Lamotrigine induced seizures in juvenile myoclonic epilepsy

Basit Öğe Kaydı
dc.contributor.authorAcar B.
dc.contributor.authorDağ E.
dc.contributor.authorTürkel Y.
dc.date.accessioned2020-06-25T15:17:19Z
dc.date.available2020-06-25T15:17:19Z
dc.date.issued2013
dc.departmentKırıkkale Üniversitesi
dc.description.abstractJuvenile myoclonic epilepsy (JME) is a common epileptic syndrome. Before the development of the new antiepileptic drugs (AEDs) after the 1990s, Valproate (VPA) was the first-line treatment in juvenile myoclonic epilepsy. However, the frequent adverse effects and the risk for teratogenicity have resulted in a search for alternative therapies especially in women. Lamotrigine (LTG), topiramate, and levetiracetam, have been used as monotherapy or adjunctive therapy for juvenile myoclonic epilepsy in small patient series. We report a case of a thirty one-years-old female suffered from severe aggravation in myoclonic and generalized tonic-clonic (GTC) seizures after decreasing the lose of VPA and initiating LTG. © 2013 OMU.en_US
dc.identifier.endpage208en_US
dc.identifier.issn13002996
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-84886295188
dc.identifier.scopusqualityN/A
dc.identifier.startpage207en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12587/2297
dc.identifier.volume30en_US
dc.indekslendigikaynakScopus
dc.language.isoen
dc.relation.ispartofOndokuz Mayis Universitesi Tip Dergisi
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntiepileptic drugen_US
dc.subjectJuvenile myoclonic epilepsyen_US
dc.subjectLamotrigineen_US
dc.subjectSeizureen_US
dc.titleLamotrigine induced seizures in juvenile myoclonic epilepsyen_US
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu